JJ Bienaimé is moving out of the C-suite after an 18-year run at BioMarin. And you likely know his successor
Feisty, stubborn Jean-Jacques Bienaimé is stepping down from the top post at BioMarin after an 18-year run with a string of highlights in 2023. And he’s handing the reins to his carefully-picked successor: Alexander Hardy, the CEO at industry stalwart Genentech.
The change at the top — as the 70-year-old Bienaimé moves to an advisory role next year after exiting the C-suite Dec. 1 — includes Richard Meier, an independent director who is moving into the role of chair of the board.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.